Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 14/20 | 0.51 |
| ▸ | HTR2A | P28223 | 4/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.51 |
| ▸ | HTR2B | P41595 | 4/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 2/20 | 0.36 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.36 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.36 |
| ▸ | SPAST | Q9UBP0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5585663 | 1.00 | HTR2C (0.51) | HTR2CHTR2AKCNH2HTR2BCYP1A2 | |
| SCHEMBL5585664 | 1.00 | HTR2C (0.51) | HTR2CHTR2AKCNH2HTR2BCYP1A2 | |
| Acetic Acid SCHEMBL6184549 | 0.95 | HTR2C (0.49) | HTR2CHTR2AKCNH2HTR2BCYP1A2 | |
| SCHEMBL5585610 | 0.82 | ADRB2 (0.53) | HTR2CHTR2AHTR2BCYP1A2CYP3A4 | |
| SCHEMBL5585237 | 0.80 | HTR2C (0.50) | HTR2CHTR2AKCNH2HTR2BCYP1A2 | |
| SCHEMBL5585267 | 0.80 | HTR2C (0.50) | HTR2CHTR2AKCNH2HTR2BCYP1A2 | |
| SCHEMBL5585322 | 0.78 | HTR2C (0.50) | HTR2CHTR2AKCNH2HTR2BCYP1A2 | |
| SCHEMBL5585640 | 0.78 | HTR2C (0.41) | HTR2CHDAC1PIM1PIM3PIM2 | |
| SCHEMBL5585869 | 0.78 | HTR2C (0.41) | HTR2CHDAC1PIM1PIM3PIM2 | |
| SCHEMBL5585643 | 0.78 | HTR2C (0.41) | HTR2CHDAC1PIM1PIM3PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1329389-C | Novel compounds and their use | BIOVITRUM AB (SE) | 2007-08-01 | — | — | CN | claimed |
| US-7229997-B2 | Compounds and their use | BIOVITRUM AB (SE) | 2007-06-12 | — | — | US | claimed |
| EP-1506185-B1 | COMPOUNDS AND THEIR USE AS INHIBITORS OF 5-HT | BIOVITRUM AB (SE) | 2006-05-24 | — | — | EP | claimed |
| CN-1701068-A | Novel compounds and their use | BIOVITRUM AB (SE) | 2005-11-23 | — | — | CN | claimed |
| JP-2005529926-A | — | — | 2005-10-06 | — | — | JP | claimed |
| EP-1506185-A1 | NOVEL COMPOUNDS AND THEIR USE | Biovitrum AB (SE) | 2005-02-16 | — | — | EP | claimed |
| US-20030232814-A1 | Novel compounds and their use | BIOVITRUM AB (PUBL) (SE) | 2003-12-18 | — | — | US | claimed |
| WO-2003097636-A1 | NOVEL COMPOUNDS AND THEIR USE | BIOVITRUM AB (SE) | 2003-11-27 | — | — | WO | claimed |
| CN-1329389-C | Novel compounds and their use | BIOVITRUM AB (SE) | 2007-08-01 | — | — | CN | disclosed |
| US-7229997-B2 | Compounds and their use | BIOVITRUM AB (SE) | 2007-06-12 | — | — | US | disclosed |
| EP-1506185-B1 | COMPOUNDS AND THEIR USE AS INHIBITORS OF 5-HT | BIOVITRUM AB (SE) | 2006-05-24 | — | — | EP | disclosed |
| CN-1701068-A | Novel compounds and their use | BIOVITRUM AB (SE) | 2005-11-23 | — | — | CN | disclosed |
| EP-1506185-A1 | NOVEL COMPOUNDS AND THEIR USE | Biovitrum AB (SE) | 2005-02-16 | — | — | EP | disclosed |
| US-20030232814-A1 | Novel compounds and their use | BIOVITRUM AB (PUBL) (SE) | 2003-12-18 | — | — | US | disclosed |
| WO-2003097636-A1 | NOVEL COMPOUNDS AND THEIR USE | BIOVITRUM AB (SE) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232814-A1 | Novel compounds and their use | GPR119, FABP4, MC4R | HTR2C 233/4885HTR2A 520/4885KCNH2 3865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.